Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Diet therapy for at least 12 weeks, or diet therapy and oral hypoglycaemic agent(s) other than SU agents for at least 12 weeks~* No previous treatment with insulin and/or SU agents~* HbA1c between 7.5% and 10.0%~* Body Mass Index (BMI) below 30.0 kg/m2~Exclusion Criteria:~* Proliferative retinopathy or maculopathy requiring acute treatment~* Impaired hepatic function~* Impaired renal function~* Cardiac diseases~* Uncontrolled hypertension~* Known hypoglycaemia unawareness or recurrent major hypoglycaemia~* Current treatment with systemic corticosteroids

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).